David S Siegel1, Meletios Dimopoulos2, Sundar Jagannath3, Hartmut Goldschmidt4, Simon Durrant5, Jonathan L Kaufman6, Xavier Leleu7, Arnon Nagler8, Fritz Offner9, Thorsten Graef10, Joseph E Eid10, Jennifer Houp10, Christine Gause10, Scott Vuocolo10, Kenneth C Anderson11. 1. Myeloma Division, Hackensack University Medical Center, Hackensack, NJ. Electronic address: dsiegel@hackensackumc.org. 2. Department of Therapeutics, University of Athens, Athens, Greece. 3. Mount Sinai Medical Center, New York, NY. 4. Universitätsklinikum Heidelberg, Heidelberg, Germany. 5. Bone Marrow Transplant Clinical Hematology Unit, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia. 6. Emory University School of Medicine, Atlanta, GA. 7. Service des Maladies du Sang, University of Lille, Lille, France. 8. Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel. 9. Universitair Ziekenhuis Gent, Ghent, Belgium. 10. Merck & Co., Inc., Kenilworth, NJ. 11. Dana-Farber Cancer Institute, Boston, MA.
Abstract
BACKGROUND: The present global, open-label, single-arm, multicenter, phase IIb study was designed to determine the efficacy and tolerability of oral vorinostat combined with standard doses of bortezomib in patients with multiple myeloma considered refractory to novel myeloma agents. PATIENTS AND METHODS: Eligible patients were age ≥ 18 years, had received ≥ 2 previous regimens, had disease refractory to ≥ 1 previous bortezomib-containing regimen, and had received ≥ 1 dose of an immunomodulatory drug (thalidomide or lenalidomide)-based regimen. The patients received 21-day cycles of bortezomib (1.3 mg/m(2) intravenously on days 1, 4, 8, and 11) plus oral vorinostat (400 mg/d on days 1-14). Oral dexamethasone, 20 mg, on the day of and the day after each dose of bortezomib could be added for patients with progressive disease after 2 cycles or no change after 4 cycles. The primary endpoint was the objective response rate. RESULTS: The objective response rate was 11.3% (95% confidence interval, 6.6%-17.7%), and the median duration of response was 211 days (range, 64-550 days). The median overall survival duration was 11.2 months (95% confidence interval, 8.5-14.4 months), with a 2-year survival rate of 32%. The frequently reported adverse events were thrombocytopenia (69.7%), nausea (57.0%), diarrhea (53.5%), anemia (52.1%), and fatigue (48.6%); the overall safety profile was consistent with that of bortezomib and vorinostat. CONCLUSION: The combination of vorinostat and bortezomib is active in patients with multiple myeloma refractory to novel treatment modalities and offers a new therapeutic option for this difficult-to-treat patient population (ClinicalTrials.gov identifier, NCT00773838).
BACKGROUND: The present global, open-label, single-arm, multicenter, phase IIb study was designed to determine the efficacy and tolerability of oral vorinostat combined with standard doses of bortezomib in patients with multiple myeloma considered refractory to novel myeloma agents. PATIENTS AND METHODS: Eligible patients were age ≥ 18 years, had received ≥ 2 previous regimens, had disease refractory to ≥ 1 previous bortezomib-containing regimen, and had received ≥ 1 dose of an immunomodulatory drug (thalidomide or lenalidomide)-based regimen. The patients received 21-day cycles of bortezomib (1.3 mg/m(2) intravenously on days 1, 4, 8, and 11) plus oral vorinostat (400 mg/d on days 1-14). Oral dexamethasone, 20 mg, on the day of and the day after each dose of bortezomib could be added for patients with progressive disease after 2 cycles or no change after 4 cycles. The primary endpoint was the objective response rate. RESULTS: The objective response rate was 11.3% (95% confidence interval, 6.6%-17.7%), and the median duration of response was 211 days (range, 64-550 days). The median overall survival duration was 11.2 months (95% confidence interval, 8.5-14.4 months), with a 2-year survival rate of 32%. The frequently reported adverse events were thrombocytopenia (69.7%), nausea (57.0%), diarrhea (53.5%), anemia (52.1%), and fatigue (48.6%); the overall safety profile was consistent with that of bortezomib and vorinostat. CONCLUSION: The combination of vorinostat and bortezomib is active in patients with multiple myeloma refractory to novel treatment modalities and offers a new therapeutic option for this difficult-to-treat patient population (ClinicalTrials.gov identifier, NCT00773838).
Authors: Thomas Martin; Rachid Baz; Don M Benson; Nikoletta Lendvai; Jeffrey Wolf; Pamela Munster; Alexander M Lesokhin; Claudine Wack; Eric Charpentier; Frank Campana; Ravi Vij Journal: Blood Date: 2017-05-08 Impact factor: 22.113
Authors: Johannes M Waldschmidt; Alexander Keller; Gabriele Ihorst; Olga Grishina; Stefan Müller; Dagmar Wider; Anna V Frey; Kristina King; Roman Simon; Annette May; Pierfrancesco Tassone; Justus Duyster; Manfred Jung; Noopur Raje; Ralph Wäsch; Monika Engelhardt Journal: Haematologica Date: 2018-04-19 Impact factor: 9.941
Authors: Nicholas Forsythe; Alaa Refaat; Arman Javadi; Hajrah Khawaja; Jessica-Anne Weir; Heba Emam; Wendy L Allen; Frank Burkamp; Vlad Popovici; Puthen V Jithesh; Claudio Isella; Melissa J Labonte; Ian G Mills; Patrick G Johnston; Sandra Van Schaeybroeck Journal: Mol Cancer Ther Date: 2018-02-26 Impact factor: 6.261
Authors: Aimée N Laporte; Jared J Barrott; Ren Jie Yao; Neal M Poulin; Bertha A Brodin; Kevin B Jones; T Michael Underhill; Torsten O Nielsen Journal: PLoS One Date: 2017-01-05 Impact factor: 3.240